Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07235150 | A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults | PHASE1 | RECRUITING | 76 | — | — | Dec 11, 2025 | Aug 24, 2027 | Mar 19, 2026 | 1 | Australia |
| NCT06994897 | A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults | PHASE1 | RECRUITING | 92 | — | — | Aug 13, 2025 | Dec 8, 2027 | Mar 20, 2026 | 1 | Belgium |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Dose A (3 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be subcutaneous (SC) |
| Cohort 2 Dose B (3 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 3 Dose C (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 4 Dose D (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 5 Dose E (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 6 Dose F (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 7 Dose G (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 8 Optional Cohort with dose to be determined, Japanese (4 active: 1 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 9 Optional Cohort with dose to be determined, Chinese (4 active: 1 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 10 Optional Cohort with dose to be determined (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 11 Optional Cohort with dose to be determined (6 active: 2 placebo) | EXPERIMENTAL | Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC |
| Cohort 1: single ascending dose | EXPERIMENTAL | Dose A (3 active: 2 placebo) |
| Cohort 2: single ascending dose | EXPERIMENTAL | Dose B (3 active: 2 placebo) |
| Cohort 3: single ascending dose | EXPERIMENTAL | Dose C (6 active: 2 placebo) |
| Cohort 4: single ascending dose | EXPERIMENTAL | Dose D (6 active: 2 placebo) |
| Cohort 5: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 6: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 7: single ascending dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 8: single dose | EXPERIMENTAL | Optional Japanese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 9: single dose | EXPERIMENTAL | Optional Chinese Cohort dose to be determined (4 active: 1 placebo) |
| Cohort 10: multiple dose | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 11 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 12 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Cohort 13 | EXPERIMENTAL | Optional Cohort with dose to be determined (6 active: 2 placebo) |
| Name | Type | Description |
|---|---|---|
| PF-07985631 | DRUG | Experimental Pfizer compound which will be SC |
| Placebo | DRUG | Placebo which will be SC |
Inclusion: 1. Between 18 and 45 years of age who are overtly healthy. 2. Japanese/Chinese cohorts only: Adult participants 18 to 55 years of age 3. Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China. Exclusion: 1. Evidence...